Therefore, the impact of these CYP2C8 polymorphisms on treatment outcome and tolerability was retrospectively assessed in two AS–AQ malaria efficacy trials conducted in Zanzibar in 2002–2005, when malaria in these islands was still characterized by high incidence[24, 25]. The gene discussed is CYP2C8; the disease is malaria.